about
Inhibition or knock out of inducible nitric oxide synthase result in resistance to bleomycin-induced lung injurySerum biomarkers in interstitial lung diseasesLower expression of platelet derived growth factor is associated with better overall survival rate of patients with idiopathic nonspecific interstitial pneumoniaBerberis vulgaris and its constituent berberine as antidotes and protective agents against natural or chemical toxicities.The preventive effect of atorvastatin on paraquat-induced pulmonary fibrosis in the ratsNitric oxide exerts protective effects against bleomycin-induced pulmonary fibrosis in mice.Involvement of hyaluronan in regulation of fibroblast phenotype.Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander?Disorders of lung matrix remodeling.Focal interstitial CC chemokine receptor 7 (CCR7) expression in idiopathic interstitial pneumonia.Gene expression profiling of familial and sporadic interstitial pneumonia.WNT7B in fibroblastic foci of idiopathic pulmonary fibrosisExpression of WNT5A in Idiopathic Pulmonary Fibrosis and Its Control by TGF-β and WNT7B in Human Lung Fibroblasts.Expression of fibroblast growth factor 9 in normal human lung and idiopathic pulmonary fibrosis.Increased Cellular NAD+ Level through NQO1 Enzymatic Action Has Protective Effects on Bleomycin-Induced Lung Fibrosis in Mice.Age-related changes in pericellular hyaluronan organization leads to impaired dermal fibroblast to myofibroblast differentiation.Gene expression profile analysis for different idiopathic interstitial pneumonias subtypes.Modulation of CD11c+ lung dendritic cells in respect to TGF-β in experimental pulmonary fibrosis.S100A9 promotes human lung fibroblast cells activation through receptor for advanced glycation end-product-mediated extracellular-regulated kinase 1/2, mitogen-activated protein-kinase and nuclear factor-κB-dependent pathways.Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury.Enhanced monocyte chemoattractant protein-3/CC chemokine ligand-7 in usual interstitial pneumonia.Two cases of interstitial pneumonitis caused by rituximab therapy.GW0742, a high affinity PPAR-β/δ agonist reduces lung inflammation induced by bleomycin instillation in mice.Skeletal muscle targeting in vivo electroporation-mediated HGF gene therapy of bleomycin-induced pulmonary fibrosis in mice.Protective effect of polyphenols in an inflammatory process associated with experimental pulmonary fibrosis in mice.Epithelial expression of TIMP-1 does not alter sensitivity to bleomycin-induced lung injury in C57BL/6 mice.Hyaluronan facilitates transforming growth factor-beta1-mediated fibroblast proliferation.Reduced expression of BMP3 contributes to the development of pulmonary fibrosis and predicts the unfavorable prognosis in IIP patients.MEK inhibition suppresses the development of lung fibrosis in the bleomycin model.
P2860
Q24813764-B5979326-8DA1-4F33-BB47-24836ECC35B4Q24815010-B86A4A4F-9E35-4675-B9C5-C9E0AA195263Q33571383-72B9C3AC-6148-487E-87C8-41F1674B276EQ33819605-EE7DB35B-21DD-47CC-9658-7E8C6BD16138Q34063857-8D314385-C31E-40F0-9AF2-5A923C0DB1EFQ34545265-61B11EC4-4C04-417A-8F03-2F063AD61BAFQ34646066-68E96677-D8EC-4416-B847-9BDAFBB3B1C6Q34882979-7361E487-30C6-44A8-BCFF-C61F671A3E55Q35628568-863A841E-68AB-48C8-9764-C909D4EFC10FQ35769497-5B158809-1479-4BDD-88CC-B97F8D6748DCQ35855118-79EC6787-0C82-45FB-AB84-D29996F5DAE3Q36341184-448D18D4-9AC3-43FF-BD1F-8A1C9899EBD1Q36742592-9CA4A883-1488-441D-AE9E-AA617B546ABAQ37122834-74D8F25A-3D34-441B-A820-0A66353A3DA4Q37362342-B5D79FEA-B893-44BE-932C-88A44FD99555Q37413650-718840C7-4BBD-4266-AAB1-9601325DF6DEQ38474468-F9CB8C15-8995-4ECC-BA40-16E4E204D685Q38756900-9021EE2B-84E5-4013-AACC-A4501644EB9CQ39150684-221C4632-ABE3-4938-BA1E-62C6062B4311Q40324025-AAF8FA4D-FEBD-42D1-8004-810848D96B96Q40546812-881B0701-B292-4925-89D3-553E6E51B961Q41869765-C6D3F5D1-E853-4F4A-94DB-3B71D9090B0FQ42756901-C3E2F3B7-2ACD-4B44-9E69-35353667F38BQ44936723-4F07CB80-1530-4442-93AA-E83D158A4137Q46675316-25BD44E5-CC3F-421E-B71E-2EAF5F2C6E44Q46820303-0CAB5C7C-3927-45AD-BE3B-57F7CF1567EDQ46824105-7A09F783-3FB6-4869-BF4F-F293FA4F510FQ47184071-DA45AF08-9398-43DA-A047-0788AEB5BB07Q54593162-2EF407EF-C276-4FEA-862B-5D711418819D
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Overview of pulmonary fibrosis.
@ast
Overview of pulmonary fibrosis.
@en
type
label
Overview of pulmonary fibrosis.
@ast
Overview of pulmonary fibrosis.
@en
prefLabel
Overview of pulmonary fibrosis.
@ast
Overview of pulmonary fibrosis.
@en
P1433
P1476
Overview of pulmonary fibrosis.
@en
P2093
Francis H Y Green
P304
P356
10.1378/CHEST.122.6_SUPPL.334S
P407
P433
P577
2002-12-01T00:00:00Z